Careers

Where Our Graduates Have Gone

Becton Dickinson
U.S. Food & Drug Adminisitration
Humacyte, Inc.
Northrup Grumman
W.L. Gore and Assoociates
Alta Vision
Zymergen, Inc.
Navigant
Moderna Therapeutics
PPD Consulting
Illumina, Inc.
Novan Therapeutics
Johnson and Johnson
NeuroPace
OncoCell MDX
Booz Allen Hamilton
Edwards Lifesciences
Medtown Ventures
BioMarin Pharmaceuticals
St. Jude Medical
Smith and Nephew
Stryker
Cook Medical
Los Alamos National Laboratory
Liquidia Technologies

Trainee Highlight

Lucinda Camras
Founder and Inventor, Alevio (formerly Camras Vision)
Ph.D. Biomedical Engineering 2013
Advisor: Professor Fan Yuan

Lucinda's academic work has resulted in 6 first-author publications and over 20 abstracts. She also has 6 patents issued or pending and has given over 10 lectures at international scientific conferences. Lucinda collaborated with her father, a glaucoma specialist, Dr. Carl Camras, MD, to create a novel device to treat glaucoma. After her father’s passing, she co-founded the company Camras Vision (now Alevio) to further develop the device that they envisioned would be the solution for glaucoma therapy. Currently, she serves as Alevio’s Chief Scientific Officer. Lucinda was able to obtain $1.2M+ in small business grant funding from the NIH and NSF to further develop the Camras Shunt and served as the principal investigator or company director on these grants.

Caroline Rhim
Executive Director, Regulatory Consulting, Medical Devices at NSF International
Ph.D. Biomedical Engineering 2009
Advisor: Professor Laura Niklason

Caroline is a regulatory professional with over ten years of experience in the medical device industry, with over seven years of FDA experience in the orthopedic and cardiovascular device space. She has expertise in navigating regulatory pathways from premarket to postmarket, including device classification and preclinical as well as clinical study design. She can advise across a broad variety of technologies that span 510(k), De Novo, investigational device exemption (IDE), and premarket approval application (PMA) regulatory pathways; Strong internal network at FDA with the ability to effectively communicate with regulatory counterparts.